Supported by Glaucoma UK (2023 Royal College of Ophthalmologists/Glaucoma UK research grant). Supported in part, by the National Institute for Health & Care Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology (DGH). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. DGH's chair at UCL is supported by funding from Glaucoma UK.
Disclosure: G. Montesano, CenterVue-iCare (C); Alcon (C); Relayer, LtD (O), Omikron (C), Thèa (C); A. Rabiolo, None; G. Ometto, Relayer, LtD (O); Alcon (C); D.P. Crabb, ANSWERS (P), T4 (P); Allergan (C), Apellis (C), Roche (C), Thea (C), Santen (F); D.F. Garway-Heath, Topcon (F); Carl Zeiss Meditec (C), CenterVue-iCare (C), Heidelberg Engineering (F), Moorfields MDT (P), ANSWERS (P), T4 (P), Visual Field Sensitivity Testing (P), Omikron (C)